Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Dose Escalation and Pharmacodynamic Study of ARQ 761 (Beta-Lapachone) in Adult Patients With Advanced Solid Tumors

NCT01502800 is registered in ClinicalTrials.gov with University of Texas Southwestern Medical Center as lead sponsor.

NCT NCT01502800
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01502800 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Dose Escalation and Pharmacodynamic Study of ARQ 761 (Beta-Lapachone) in Adult Patients With Advanced Solid Tumors
Lead sponsor
University of Texas Southwestern Medical Center
Phase
Phase 1
Overall status
Completed
Start date
December 29, 2011
Completion date
March 31, 2019
Enrollment
91 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors